JPM23 Special: Advancing RNA Therapeutics, Geoff Nosrati, CBO, Nutcracker Therapeutics

Synopsis: Geoff Nosrati is the Chief Business Officer of Nutcracker Therapeutics, an early-stage company that is pioneering a revolutionary therapeutic development and manufacturing platform designed to enable the advancement of RNA-based treatments for as many diseases as possible. Early in his career, Geoff joined McKinsey & Co. as a consultant, working with biotech and pharma companies. He then worked with several small oncology-focused biotech companies, including Aduro Biotech and ImmunoScape before joining Nutcracker. In this episode he provides his perspective on the RNA space as it stands right now and the diversity of applications that exist, some of the opportunities and challenges of working on an RNA therapeutic, how he thinks about indication selection, Nutcracker’s complete RNA platform and the work they’re doing to develop therapeutics, and where the company is now from a building and R&D perspective. Biography: As Chief Business Officer, Geoff oversees Nutcracker’s business development and corporate strategy functions. Prior to Nutcracker, Geoff served as Chief Business Officer at ImmunoScape and as SVP of Strategy and Corporate Development at Aduro Biotech. Earlier in his career, Geoff was a consultant with McKinsey & Co., where he primarily served clients across the pharmaceutical and biotechnology industries. Geoff was awarded a B.S. in Chemistry from Duke University and received his Ph.D. in Biochemistry and Molecular Biology from the University of California, Los Angeles.